XML 49 R34.htm IDEA: XBRL DOCUMENT v3.25.0.1
Segment Reporting (Tables)
12 Months Ended
Dec. 31, 2024
Segment Reporting  
Schedule of reportable segment profit and loss including significant expense categories

The following table presents reportable segment profit and loss, including significant expense categories, attributable to the Company’s reportable segment for the periods presented:

Year Ended December 31,

    

2024

    

2023

Expenses1:

 

  

 

  

Research and development:

 

  

 

  

Navenibart

$

32,401

$

24,186

STAR-0310

 

15,497

 

677

Employee expenses

 

14,415

 

9,859

General and administrative:

 

  

 

  

Program support2

 

1,021

 

476

Employee expenses

 

11,575

 

9,128

Stock-based compensation expense

 

12,907

 

6,313

Consulting and professional services expenses

 

17,952

 

9,382

Other segment expenses3

 

5,790

 

7,810

Acquired in-process research and development4

 

 

15,199

Other income, net5

 

(17,298)

 

(10,139)

Segment net loss

$

94,260

$

72,891

(1) The significant expense categories and amounts align with segment level information that is regularly provided to the CODM.

(2) General and administrative program support expense includes commercial costs incurred in support of navenibart and STAR-0310, and patient advocacy costs incurred in support of navenibart and STAR-0310.

(3) Other segment expense includes: costs incurred in support of overall research and development activities and non-specific programs, facilities expense, office expense, insurance expense and depreciation and amortization.

(4) Acquired in-process research and development includes expense associated with entering into a license agreement as discussed in Note 1, “Organization and Operations”.

(5) Other income, net, consists primarily of interest income on investments, as further described in Note 4, “Short-Term Investments”. For the years ended December 31, 2024 and 2023, the Company recognized interest income of $17.4 million and $10.2 million, respectively.